Subscribe
shutterstock_1548704417_nitpicker-1
26 January 2023Big PharmaLiz Hockley

BMS sues AstraZeneca for infringing cancer treatment drug

US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More on this story

Generics
BMS says Hengrui’s Abraxane infringes
13 May 2022   A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane infringes a patent.
Generics
Gilead, BMS, Janssen facing HIV generic antitrust suit
16 December 2021   Gilead, Bristol-Myers Squibb and Janssen are facing accusations that they suppressed competition in the market for drugs used to treat the human immunodeficiency virus.
Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York